
USD $6744.60
Retevmo (Selpercatinib) is a targeted therapy designed to treat specific types of cancer, particularly those associated with RET gene alterations. This innovative medication works by inhibiting the activity of the RET protein, which plays a crucial role in the growth and spread of cancer cells. By blocking this pathway, Selpercatinib helps to slow down or stop the progression of tumors, providing a more effective treatment option for patients.